Cargando…
30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective
Emerging evidence from the numerous clinical trials involving cytokine-induced killer (CIK) cell therapy suggests that its optimization in combination with other contemporary cancer therapies in a complementary manner (rather than as competition) will be a key to combat cancer.
Autores principales: | Sharma, Amit, Schmidt-Wolf, Ingo G. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662881/ https://www.ncbi.nlm.nih.gov/pubmed/34886895 http://dx.doi.org/10.1186/s13046-021-02184-2 |
Ejemplares similares
-
Editorial to Special Issue “Glioblastoma: Recapitulating the Key Breakthroughs and Future Perspective”
por: Sharma, Amit, et al.
Publicado: (2023) -
CIK Cells and HDAC Inhibitors in Multiple Myeloma
por: Stephan, David, et al.
Publicado: (2017) -
A Low Dose of Pure Cannabidiol Is Sufficient to Stimulate the Cytotoxic Function of CIK Cells without Exerting the Downstream Mediators in Pancreatic Cancer Cells
por: Garofano, Francesca, et al.
Publicado: (2022) -
Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies
por: Schmeel, Frederic Carsten, et al.
Publicado: (2014) -
Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma
por: Zhang, Ying, et al.
Publicado: (2022)